Drug Topics December 2022

Take a look back at the top 15 articles that we published in 2022.

Understanding the relationship between psoriasis and psoriatic arthritis can help.

Examining what immunotherapy can do for skin cancer treatment.

Valerie D. Callender, MD, FAAD, offers a look at the newest treatments available for acne and rosacea.

Immune checkpoint inhibitor therapy does not appear to increase complication rates in patients undergoing dermatologic procedures.

Several factors predict itch-specific quality of life in patients with chronic itch.

Biosimilar medications stand to significantly increase cost savings for patients.

When dealing with marginalized and underserved populations, it is important to understand barriers to care and why they exist.

With increasing use of telehealth, patients need access to resources that let them get the most out of the experience.

With supply chain issues impacting many industries, drug shortages have occurred. How does the FDA address them?

New pathways of care are needed to improve health care spending.

By offering resources such as free samples and generic alternatives, pharmacists can help patients lower costs.

Social support and education may be the solution.

Study participants experienced better outcomes vs standard of care with a digital inhaler system.

Relyvrio is intended to slow the disease progression of amyotrophic lateral sclerosis.

When it comes to practicing pharmacy, do titles and degrees actually matter?

Online portals are accessible via tablet or computer and can streamline the mental health screening process.

Investigators set out to evaluate how medication access for certain rheumatic conditions has changed since June 2022.

Timing of treatment initiation is crucial for patients with cancer.

Thinking carefully about how data are collected is the first step improving health outcomes.

Addressing hesitancy is more than just offering pertinent information.

Working collaboratively can be key to either avoiding a PBM audit altogether or making the process as painless as possible.

Results of multiple studies were presented at IDWeek 2022.

After multiple approvals and emergency use authorizations, It’s time to take stock of the state of pediatric COVID-19 vaccines.